Obsessive–compulsive disorder

BrainsWay to Present at the Oppenheimer 31st Annual Healthcare Conference

Retrieved on: 
Monday, March 8, 2021
Branches of biology, Neuroscience, Neurotechnology, Neurophysiology, Neuropsychology, Treatment of depression, Electrotherapy, Brainsway, Transcranial magnetic stimulation, Neurostimulation, Obsessive–compulsive disorder, Major depressive disorder

BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neurostimulation products using the Companys proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology.

Key Points: 
  • BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neurostimulation products using the Companys proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology.
  • The Company received marketing authorization from the U.S. Food and Drug Administration (FDA) for its products for a variety of patient populations, including in 2013 for patients with major depressive disorder (MDD), in 2018 for patients with obsessive-compulsive disorder (OCD), and in 2020 for patients with smoking addiction.
  • BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders.

Therapeutic Solutions International Spin-Off Campbell Neurosciences Demonstrates Preliminary Efficacy of First Blood-Based Test for Gambling Addiction: Kaihani Score™

Retrieved on: 
Thursday, February 25, 2021
Psychiatric diagnosis, Psychiatry, Behavioral addiction, Human behavior, Anxiety disorders, Psychology, Problem gambling, Abnormal psychology, Compulsive behavior, Addiction, Obsessive–compulsive disorder

Preliminary data revealed a profound increase in the neuromodulatory protein assessed by Kaihani Score which correlated with gambling addiction severity.

Key Points: 
  • Preliminary data revealed a profound increase in the neuromodulatory protein assessed by Kaihani Score which correlated with gambling addiction severity.
  • Four patients with no gambling addiction had 13.41.6 ng/ml, four patients with moderate gambling addiction had 37.45.6 ng/ml, and four patients with several gambling addiction had 57.76.3 ng/ml.
  • Severity of gambling addiction was assessed using Pathological Gambling Adaptation of the Yale-Brown Obsessive Compulsive Scale (PG-YBOCS).
  • Campbell Neurosciences, a spin-off of the biotherapeutics company Therapeutic Solutions International is named after Kathleen Campbell, mother of Kalina O'Connor, who was a victim of suicide.

Global Pharmaceutical Treatments for Mental Health Disorders Market (2020 to 2025) - Conditions are Likely to Rise in the Near Future Due to the Consequences of COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 24, 2021
Pharmaceutical, Health, Mental health, Psychiatry, Medical specialties, Health, Psychiatric diagnosis, Abnormal psychology, Mental disorder, Psychiatric assessment, Psychopathology, Suffering, Cognitive behavioral therapy, Social distancing, Obsessive–compulsive disorder

Evaluation of current market trends, market size, market forecast, pipeline analysis of new products, and regulatory scenarios and detailed analysis of drivers, challenges, and opportunities affecting market growth

Key Points: 
  • Evaluation of current market trends, market size, market forecast, pipeline analysis of new products, and regulatory scenarios and detailed analysis of drivers, challenges, and opportunities affecting market growth
    Description of biological factors such as anatomical, chemical and genetic traits, and psychological reasons such as conflict or trauma on the mental health and discussion on effect of COVID-19 pandemic, social distancing and social isolation on the mental health conditions
    A look at the markets for treatment of psychiatric disorders such as depression, anxiety and obsessive-compulsive disorder (OCD) and their co relation with COVID-19
    Details of technological advances and improvement in the development of pharmacological treatments, digital therapeutics (DTx) and cognitive behavioural therapy (CBT)
    Information on tele mental health software such as ReSet, Pears Somryst and Alkili's EndeavorRx which offers personalized treatment strategies and behavioural healthcare platform which plays an important role in the management of mental health disorders
    Snapshot of leading mental health conditions, and products in phase III development for selected psychiatric disorders
    Analysis of recent product developments including pharmacological and digital therapeutics, late-stage pipeline products and points of differentiation from existing therapies
    Market research suggests that mental health conditions are likely to rise in the near future due to the consequences of COVID-19 pandemic, social distancing and social isolation.

BrainsWay Announces Publication of New Real-World OCD Data for its Deep TMS System in Journal of Psychiatric Research

Retrieved on: 
Wednesday, November 11, 2020
Branches of biology, Neuroscience, Neurotechnology, Neurophysiology, Neuropsychology, Treatment of depression, Electrotherapy, Transcranial magnetic stimulation, Brainsway, Obsessive–compulsive disorder, TMS, Abraham Zangen

The patients were treated with BrainsWays proprietary H7-coil deep transcranial magnetic stimulation (Deep TMS) system, the first non-invasive medical device cleared by the U.S. Food and Drug Administration (FDA) for OCD.

Key Points: 
  • The patients were treated with BrainsWays proprietary H7-coil deep transcranial magnetic stimulation (Deep TMS) system, the first non-invasive medical device cleared by the U.S. Food and Drug Administration (FDA) for OCD.
  • It is gratifying to see the real-world utility and efficacy of Deep TMS for OCD under clinical conditions, stated Aron Tendler, M.D., Chief Medical Officer of BrainsWay.
  • We view the publication of these data in the prestigious Journal of Psychiatric Research as further validation of BrainsWays leadership position in TMS.
  • Importantly, we intend to leverage these compelling results with payors in our efforts to secure reimbursement for Deep TMS in OCD.

Psychedelic Drugs Offering New Hope for Treatment of Debilitating Disorders

Retrieved on: 
Thursday, October 15, 2020
Psychiatry, Hallucinations, Psychedelic drug, Obsessive–compulsive disorder, Drug, Mind, Articles, Heffter Research Institute

To view the full publication, Multi-Billion-Dollar Market Forecast in Psychedelic Therapeutics, please visit: https://nnw.fm/rcMI5

Key Points: 
  • To view the full publication, Multi-Billion-Dollar Market Forecast in Psychedelic Therapeutics, please visit: https://nnw.fm/rcMI5
    Compelling evidence of the therapeutic benefits of psychedelic drugs appears in multiple scientific studies.
  • There is new hope for treating such debilitating disorders as depression, anxiety, post-traumatic stress disorder, anorexia, obsessive-compulsive disorder, and addiction.
  • With more than $6.8 billion on the line by 2027, companies at the vanguard of the psychedelic therapeutic drug market could reap enormous benefits in the coming years.
  • A pioneer in the psychedelic sector, CYBIN is working toward becoming the first life sciences company to bring a psilocybin drug targeting MDD to market.

BrainsWay Debuts “#TheRealOCD” Campaign and Video on Obsessive-Compulsive Disorder (OCD)

Retrieved on: 
Tuesday, October 13, 2020
Anxiety disorders, Psychiatry, Branches of biology, Psychiatric diagnosis, Neuroscience, Magical thinking, Obsessive–compulsive disorder, RTT, Brainsway, Compulsive behavior

(NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced noninvasive treatment of brain disorders, today announced its #TheRealOCD campaign in conjunction with Obsessive-Compulsive Disorder (OCD) Awareness Week, which takes place October 11 17, 2020.

Key Points: 
  • (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced noninvasive treatment of brain disorders, today announced its #TheRealOCD campaign in conjunction with Obsessive-Compulsive Disorder (OCD) Awareness Week, which takes place October 11 17, 2020.
  • The campaign features an original video starring mental health influencers Kait Miller ( @kaitgmiller) and Rachel Novak ( @rachel.novak ) who discuss the common misuse of the phrase OCD in popular culture.
  • The video also features real stories of patients actually suffering from OCD, and reveals insights on the true nature of living with this traditionally difficult-to-treat disorder.
  • We hope this video facilitates increased education around what real OCD looks like, and conveys that it can be successfully treated.

Dr. Ashraf Hanna's Innovative Ketamine Protocol Delivers a Complete Sustained Remission in a Patient with Depression and Suicidal Ideation

Retrieved on: 
Tuesday, October 6, 2020
Drugs, Psychoactive drugs, RTT, Branches of biology, Psychiatric diagnosis, Antidepressants, Amines, Ketamine, Treatment-resistant depression, Post-traumatic stress disorder, Selective serotonin reuptake inhibitor, Obsessive–compulsive disorder

Many prominent psychiatrists describe Ketamine as fast and effective with results in a matter of days or hours which is a huge advantage over traditional SSRIs.

Key Points: 
  • Many prominent psychiatrists describe Ketamine as fast and effective with results in a matter of days or hours which is a huge advantage over traditional SSRIs.
  • IV Ketamine therapy is only reserved for those patients that have treatment-resistant depression and have failed conventional therapy.
  • I then wanted to expand the treatment for PTSD, depression, bipolar depression and obsessive compulsive disorders.
  • For more information regarding IV Ketamine Infusion therapy for Depression and PTSD , please visit: https://www.ivketamine.com orcall 727-538-2646

Michigan Advanced Psychiatry Opens New Facility To Offer Deep Transcranial Magnetic Stimulation (Deep TMS) for Patients With Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD)

Retrieved on: 
Thursday, October 1, 2020
Psychiatry, Medicine, Neuroscience, Neurotechnology, Neurophysiology, Neuropsychology, Treatment of depression, Electrotherapy, Transcranial magnetic stimulation, Brainsway, Obsessive–compulsive disorder, Major depressive disorder

The clinic will offer BrainsWays Deep Transcranial Magnetic Stimulation (Deep TMS ) for major depressive disorder (MDD) and obsessive-compulsive disorder (OCD).

Key Points: 
  • The clinic will offer BrainsWays Deep Transcranial Magnetic Stimulation (Deep TMS ) for major depressive disorder (MDD) and obsessive-compulsive disorder (OCD).
  • BrainsWays Deep TMS device noninvasively administers magnetic waves through a cushioned helmet to target deep structures of the brain that impact depression symptoms.
  • Michigan Advanced Psychiatry offers Deep TMS, Ketamine treatments, evaluation and medication management services.
  • Established in 2020 by Dr. Andrew Schmale, Michigan Advanced Psychiatry is a mental health clinic dedicated to providing advanced treatments for mental health disorders.

Deep Brain Stimulation (DBS) Systems Market Worth USD 2,122.8 Million By 2027 | Emergen Research

Retrieved on: 
Wednesday, September 16, 2020
Medicine, Clinical medicine, Neuroscience, Neurotechnology, Electrotherapy, Medical devices, Neurosurgical procedures, Deep brain stimulation, Tourette syndrome, Brain stimulation, Obsessive–compulsive disorder, Brain stimulation

High prevalence of such diseases among elderly coupled with rising geriatric population are fuelling up the demand for the deep brain stimulation systems worldwide.

Key Points: 
  • High prevalence of such diseases among elderly coupled with rising geriatric population are fuelling up the demand for the deep brain stimulation systems worldwide.
  • In addition, increasing incidences associated with depression, essential tremor and obsessive compulsive disorder (OCD) are further multiplying the demand of deep brain stimulation systems in the industry.
  • The systems directed in deep brain stimulation safeguards minimal damage to the surrounding brain tissues.
  • To get leading market solutions, visit the link below: https://www.emergenresearch.com/industry-report/deep-brain-stimulation-s...
    Emergen Research have segmented Deep Brain Stimulation (DBS) Systems Market on the basis of product, application, end use and region:
    Product Outlook (Revenue in Million USD; 20172027)
    Application Outlook (Revenue in Million USD; 20172027)

Experienced Business Leader Expands Caring Transitions into Lebanon, NJ

Retrieved on: 
Wednesday, September 9, 2020
Abnormal psychology, Compulsive decluttering, Obsessive–compulsive disorder, Estate sale, Transitions

Caring Transitions' specially-trained professionals handle decluttering, organizing, packing, moving, resettling, in-home estate sales and online auctions, home clean-outs, estate clearing and preparing homes for market.

Key Points: 
  • Caring Transitions' specially-trained professionals handle decluttering, organizing, packing, moving, resettling, in-home estate sales and online auctions, home clean-outs, estate clearing and preparing homes for market.
  • Mauro, who is a Certified Senior Relocation and Transitions Specialist, is an experienced business leader.
  • Between my time in retail, my experience in logistics and my personal experience, Caring Transitions was the perfect fit," Mauro said.
  • Caring Transitions of Lebanon is bonded and insured and employees are background checked.